ROS1-positive – Talk Bio

Actionable Insights Powered by AI

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib in TKI Pre-treated Advanced ROS1-positive NSCLC

3 weeks ago talkbio0Tagged acceptance, ARROS-1 trial, Breakthrough Therapy, Clinical Nurse Specialists, Identifier, New Drug Application, Non-Small Cell Lung Carcinoma, Nuvalent, orphan drug designation, PDUFA, Penetration, pre-treated, Protein-tyrosine kinase inhibitor, ROS1-positive, United States Food and Drug Administration, zidesamtinib

Nuvalent; zidesamtinib; FDA acceptance; New Drug Application (NDA); ROS1-positive NSCLC; tyrosine kinase inhibitor (TKI) pre-treated; ARROS-1 trial; PDUFA date; CNS penetration; breakthrough therapy designation; orphan drug designation

Nuvation Bio Advances with Pooled Data for ROS1-positive Lung Cancer Treatment, Eyes FDA Submission

1 year ago talkbio0Tagged Bio, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Nuvation, ROS1-positive, Submission, taletrectinib, TRUST-I, TRUST-II, United States Food and Drug Administration

Nuvation Bio, ROS1-positive NSCLC, taletrectinib, TRUST-I, TRUST-II, FDA submission, lung cancer treatment